Alar Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Alar Pharmaceuticals has a total shareholder equity of NT$2.5B and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$2.5B and NT$55.9M respectively. Alar Pharmaceuticals's EBIT is NT$385.8M making its interest coverage ratio -7.2. It has cash and short-term investments of NT$2.4B.
Key information
0%
Debt to equity ratio
NT$0
Debt
| Interest coverage ratio | -7.2x |
| Cash | NT$2.42b |
| Equity | NT$2.47b |
| Total liabilities | NT$55.93m |
| Total assets | NT$2.52b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: 6785's short term assets (NT$2.4B) exceed its short term liabilities (NT$54.0M).
Long Term Liabilities: 6785's short term assets (NT$2.4B) exceed its long term liabilities (NT$2.0M).
Debt to Equity History and Analysis
Debt Level: 6785 is debt free.
Reducing Debt: 6785 has no debt compared to 5 years ago when its debt to equity ratio was 0.9%.
Debt Coverage: 6785 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 6785 has no debt, therefore coverage of interest payments is not a concern.